国际医学放射学杂志IntJMedRadiol2021Jan鸦44穴1雪[23]TakahashiM,KoLW,KulathingalJ,etal.Oxidativestress-inducedphosphorylation,degradationandaggregationofalpha-synucleinarelinkedtoupregulatedCK2andcathepsinD[J].EurJNeurosci,2007,26:863-874.DOI:10.1111/j.1460-9568.2007.05736.x.[24]LiD,HuiES,ChanQ,etal.QuantitativesusceptibilitymappingasanindicatorofsubcorticalandlimbicironabnormalityinParkinson’sdiseasewithdementia[J].NeuroimageClin,2018,20:365-373.DOI:10.1016/j.nicl.2018.07.028.[25]UchidaY,KanH,SakuraiK,etal.Voxel-basedquantitativesusceptibilitymappinginParkinson’sdiseasewithmildcognitiveimpairment[J].MovDisord,2019,34:1164-1173.DOI:10.1002/mds.27717.[26]ThomasG,LeylandLA,SchragAE,etal.BrainirondepositionislinkedwithcognitiveseverityinParkinson’sdisease[J].JNeurolNeurosurgPsychiatry,2020,91:418-425.DOI:10.1136/jnnp-2019-322042.[27]KodlCT,SeaquistER.Cognitivedysfunctionanddiabetesmellitus[J].EndocrRev,2008,29:494-511.DOI:10.1210/er.2007-0034.[28]WangH,LiH,JiangX,etal.Hepcidinisdirectlyregulatedbyinsulinandplaysanimportantroleinironoverloadinstreptozotocin-induceddiabeticrats[J].Diabetes,2014,63:1506-1518.DOI:10.2337/db13-1195.[29]YangQ,ZhouL,LiuC,etal.Brainirondepositionintype2diabetesmellituswithandwithoutmildcognitiveimpairment-aninvivosusceptibilitymappingstudy[J].BrainImagingBehav,2018,12:1479-1487.DOI:10.1007/s11682-017-9815-7.[30]NishidaK,GarringerHJ,FutamuraN,etal.Anovelferritinlightchainmutationinneuroferritinopathywithanatypicalpresentation[J].JNeurolSci,2014,342:173-177.DOI:10.1016/j.jns.2014.03.060.[31]ChenL,WeiX,LiuC,etal.Brainirondepositioninprimaryinsomnia-Aninvivosusceptibility-weightedimagingstudy[J].BrainBehav,2019,9:e01138.DOI:10.1002/brb3.1138.[32]LuL,CaoH,WeiX,etal.Irondepositionispositivelyrelatedtocognitiveimpairmentinpatientswithchronicmildtraumaticbraininjury:assessmentwithsusceptibilityweightedimaging[J].BiomedResInt,2015,2015:470676.DOI:10.1155/2015/470676.[33]RazE,JensenJH,GeY,etal.Brainironquantificationinmildtraumaticbraininjury:amagneticfieldcorrelationstudy[J].AJNR,2011,32:1851-1856.DOI:10.3174/ajnr.A2637.[34]NeemaM,AroraA,HealyBC,etal.DeepgraymatterinvolvementonbrainMRIscansisassociatedwithclinicalprogressioninmultiplesclerosis[J].JNeuroimaging,2009,19:3-8.DOI:10.1111/j.1552-6569.2008.00296.x.[35]FujiwaraE,KmechJA,CobzasD,etal.Cognitiveimplicationsofdeepgraymatterironinmultiplesclerosis[J].AJNR,2017,38:942-948.DOI:10.3174/ajnr.A5109.[36]MiyakeZ,NakamagoeK,YoshidaK,etal.Deferasiroxmightbeef-fectiveformicrocyticanemiaandneurologicalsymptomsassociatedwithaceruloplasminemia:acasereportandreviewoftheliterature[J].IntMed,2020,59:1755-1761.DOI:10.2169/internalmedicine.4178-19.(收稿2020-03-16)本刊作者署名及基金标注的规定为避免文章署名纠纷,严防署名学术不端,本刊就作者署名及基金标注相关事宜规定如下:1.作者署名排序以初次来稿为准,投稿系统中的作者姓名及顺序应与投稿文件(word文件)一致。如第一作者变更,须说明具体原因,同时提供原作者的自愿变更声明及盖有公章的单位证明。2.凡需要标注通信作者的稿件必须在投稿时注明。原始稿件及修改稿件中必须有明确标注,其他任何形式的说明一概无效。本刊不予标注“并列第一作者”和“并列通信作者”;如通信作者为第一作者,不予标注。3.投稿同时须上传单位介绍信(扫描文件或高清照片)至投稿系统。文稿内包含的资料如非第一作者现工作单位的,必须有资料来源单位人员参与并署名,或由资料来源单位出具允许发表的证明。4.